Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
J.J.W.M. Janssen*, B. Lowenberg, M. Manz, B.J. Biemond, P.E. Westerweel, S.K. Klein, M. Fehr, H.A.M. Sinnige, A. Efthymiou, M.C.J.C. Legdeur, T. Pabst, M. Gregor, M.W.M. van der Poel, D. Deeren, L.W. Tick, M. Jongen-Lavrencic, F. van Obbergh, R.S. Boersma, O. de Weerdt, Y. ChalandonD. Heim, O. Spertini, G. van Sluis, C. Graux, G. Stussi, Y. van Norden, G.J. Ossenkoppele
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome'. Together they form a unique fingerprint.